The use of pazopanib in the treatment of disseminated soft tissue sarcoma: personal experience


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background. Data from the phase 3, randomized, multicentre PALETTE clinical trial led to the approval of pazopanib as an option for the treatment of patients with chemoresistant soft tissue sarcoma (STS). Presumably, the results of a registration study and data obtained in the course of practical application may differ due to the heterogeneity of patients and varying degrees of pretreatment. Objective. Comparison of the results of the phase 3 registration PALETTE study with the results obtained in the framework of our own clinical practice. Methods. We analyzed data from 38 patients who received pazopanib for STS of various histological subtypes in the dissemination stage at the N.N. Petrov National Research Center of Oncology in the period from 2013 to 2021. The end point of the study was progression-free survival (PFS). Results. The most common morphological subtype of STS was leiomyosarcoma (39.5%). Pazopanib was started after progression on 2-4 different drug regimens. The duration of treatment varied from 0.9 to 68.9 months. The median PFS was 4.0 months. Conclusion. The data obtained are comparable with those of the international PALETTE clinical trial, which confirms the efficacy of pazopanib in this cohort of patients.

全文:

受限制的访问

作者简介

Svetlana Protsenko

N.N. Petrov National Research Center of Oncology

Email: s.protsenko@list.ru
Dr. Sci. (Med.), Prof., Head of the Department of Chemotherapy and Innovative Technologies St. Petersburg, Russia

G. Teletaeva

N.N. Petrov National Research Center of Oncology

St. Petersburg, Russia

D. Latipova

N.N. Petrov National Research Center of Oncology

St. Petersburg, Russia

A. Semenova

N.N. Petrov National Research Center of Oncology

St. Petersburg, Russia

A. Novik

N.N. Petrov National Research Center of Oncology

St. Petersburg, Russia

Yu. Komarov

N.N. Petrov National Research Center of Oncology

St. Petersburg, Russia

Sh. Dzhalilova

N.N. Petrov National Research Center of Oncology

St. Petersburg, Russia

A. Malygin

N.N. Petrov National Research Center of Oncology

St. Petersburg, Russia

E. Degtiareva

N.N. Petrov National Research Center of Oncology

St. Petersburg, Russia

参考

  1. Каприн А.Д., Старинский В.В., Петрова ГВ. Состояние онкологической помощи населению России в 2017 году. М., 2018. 236 с.
  2. Hoang N.T., Acevedo L.A., Mann M.J., Tolani B. A review of soft-tissue sarcomas: translation of biological advances into treatment measures. Cancer Manag Res. 2018;10:1089-114. doi: 10.2147/CMAR.S159641.
  3. Seetharam M., Kolla K.R., Chawla S.P Metastatic Soft Tissue Sarcomas: A Review of Treatments and New Pharmacotherapies. Clin Oncol. 2018;3:1426.
  4. Frezza A.M., Stacchiotti S., Gronchi A. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. BMC Med. 2017;15(1):109. doi: 10.1186/s12916-017-0872-y.
  5. Miyamoto S., Kakutani S., Sato Y, et al. Drug review: Pazopanib. Jpn J Clin Oncol. 2018;48(6):503-13. doi: 10.1093/jjco/hyy053.
  6. Lee A.T.J., Jones R.L., Huang P.H. Pazopanib in advanced soft tissue sarcomas. Signal Transduct Target Ther. 2019;17;4:16. doi: 10.1038/s41392-019-0049-6.
  7. FDA approves Votrient for advanced soft tissue sarcoma. URL: https://www.drugs.com/newdrugs/fda-approves-votrient-advanced-soft-tissue-sarcoma-3199.html
  8. Podar K., Tonon G., Sattler M., et al. The molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006;103(51):19478-83. doi: 10.1073/pnas.0609329103.
  9. Glade Bender J.L., Lee A., Reid J.M., et al. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. J Clin Oncol. 2013;31(24):3034-43. doi: 10.1200/JCO.2012.47.0914.
  10. Sleijfer S., Ray-Coquard I., Papai Z., et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126-32. doi: 10.1200/JCO.2008.21.3223.
  11. Van der Graaf W.T., Blay J.Y, Chawla S.P, et al. EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2022
##common.cookie##